Connect Biopharma

Forecast & Rating7 analysts currently cover Connect Biopharma, with about 100.0% giving a positive rating — meaning they expect the stock to rise. The average price target is $6.00, about 782.2% upside from the current price of $0.68. Price targets range from $4.00 to $9.00 — a wide spread, showing clear disagreement over just how much Connect Biopharma can rise. Historically, about 2.7% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study Connect Biopharma closely still see room for the stock to rise. Data as of Nov 1, 2026; for reference only and not investment advice.